SuperworthSeres Therapeutics revenue MCRB
Sales by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $1.9M
- Latest quarter, Q2 FY26
- $736K
- Fiscal year 2025
- $789K
Seres Therapeutics' revenue was $1.9M over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $736K.
Over the five fiscal years to FY2025 it shrank 53% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $789K | n/a |
| FY2024 | $0 | −100% |
| FY2023 | $126.3M | +1672% |
| FY2022 | $7.1M | −95% |
| FY2021 | $144.9M | +336% |
| FY2020 | $33.2M | −4% |
| FY2019 | $34.5M | +22% |
| FY2018 | $28.3M | −12% |
| FY2017 | $32.1M | +47% |
| FY2016 | $21.8M | n/a |
| FY2015 | $0 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $736K | n/a | $1.9M | |
| Q1 FY26 | $358K | n/a | $1.1M | |
| Q4 FY25 | $438K | n/a | $789K | |
| Q3 FY25 | $351K | n/a | $351K | |
| Q2 FY25 | $0 | n/a | $0 | |
| Q1 FY25 | $0 | n/a | $0 | |
| Q4 FY24 | $0 | −100% | $0 | |
| Q3 FY24 | $0 | −100% | $64K | |
| Q2 FY24 | $0 | −100% | $374K | |
| Q1 FY24 | $0 | n/a | $126.8M | |
| Q4 FY23 | $64K | −93% | $126.3M | |
| Q3 FY23 | $310K | −91% | $127.2M |
Against its peers
Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| MCRBSeres Therapeutics | $1.9M | |
| ATNMActinium Pharmaceuticals | n/m | |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| Peer median | $114.8M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Seres Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.